

Pre-Approval Tuberculosis Treatment Initiative(PATTI)

Area/Type: ACC

Sponsor/Support: OCA

Length/Project Status: 24 months; ONGOING



TRANSFORMATIONAL
INVESTMENT
CAPACITY

Project Summary

Problem

Rising **resistance to key drugs** used in TB treatment is creating an **urgent medical and public health crisis**, leaving patients with expanded drug-resistant TB **without effective treatment options**.

Proposed Solution

The project aims to **establish a Pre-Approval Access (PAA) Framework** to ensure timely, ethical, and safe **access to potentially life-saving experimental TB drugs** for patients with no approved treatment options. Starting in **MSF sites in high-burden settings**, it will **gradually expand to partners and countries**, with the ultimate **goal of building a sustainable, scalable global PAA platform** for investigational TB drugs, that could later extend to other disease areas.



Potential Impact

- **Enables ethical and safe access to investigational TB drugs**, providing a **life-saving intervention**
- Positions **MSF as a global catalyst for equitable access to new TB medicines** in a currently underfunded area.

Viability

- **Directly responds to the needs of MSF TB projects**
- Leverages **strong partnerships with key stakeholders** to maximise impact and extend access beyond MSF patients.

Risk Mitigation

- **Builds on strong and proven MSF's experience**
- Applies a phased rollout to manage risk.
- Mitigates safety and liability risks through an **expert clinical advisory committee and robust pharmacovigilance**.

Scalability

- Includes **early plans to transition the PAA platform to global partners** (Unitaid, WHO, the BETTER project)
- **Generates and documents evidence and lessons learned** for internal and external dissemination